This has led to speculation that the use of anti-IL-17 antibodies may be a promising drug class to ameliorate GI dysfunction in stroke patients, since anti-IL-17 antibodies are under investigation as a potentially promising therapeutic target for other inflammatory diseases [118,119,120]. Here, IL17A is linked to stroke disorder.